Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Mandalà

Showing results (1-10 of 169) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Is the pooled analysis of the north central cancer treatment group phase III trials N9741 and N9841 biased?Mario Mandalà, Federica Grosso
Handbook of Experimental Pharmacology|February 27, 2017
Immunotolerance as a Mechanism of Resistance to Targeted Therapies in MelanomaMario Mandalà, Daniela Massi
Melanoma Management|September 8, 2018
Immunohistochemistry for an improved clinical workflow in the era of personalized melanoma therapy?Daniela Massi, Mario Mandalà
Expert Review of Anticancer Therapy|April 21, 2011
The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancerMario Mandalà, Carlo Tondini
Thrombosis Research|May 4, 2010
Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and managementMario Mandalà, Roberto Labianca,
Expert Opinion on Drug Safety|August 29, 2020
Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patientsAlice Indini, Mario Mandalà
Current Opinion in Obstetrics & Gynecology|February 24, 2006
Locally advanced breast cancerSandro Barni, Mario Mandalà
Virchows Archiv : an International Journal of Pathology|December 16, 2018
Rational combination of cancer immunotherapy in melanomaMario Mandalà, Piotr Rutkowski
Critical Reviews in Oncology/Hematology|February 19, 2013
Targeting BRAF in melanoma: biological and clinical challengesMario Mandalà, Christiane Voit
Virchows Archiv : an International Journal of Pathology|February 4, 2014
Tissue prognostic biomarkers in primary cutaneous melanomaMario Mandalà, Daniela Massi
Pageof 17

Showing results (1-10 of 169) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Is the pooled analysis of the north central cancer treatment group phase III trials N9741 and N9841 biased?Mario Mandalà, Federica Grosso
Handbook of Experimental Pharmacology|February 27, 2017
Immunotolerance as a Mechanism of Resistance to Targeted Therapies in MelanomaMario Mandalà, Daniela Massi
Melanoma Management|September 8, 2018
Immunohistochemistry for an improved clinical workflow in the era of personalized melanoma therapy?Daniela Massi, Mario Mandalà
Expert Review of Anticancer Therapy|April 21, 2011
The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancerMario Mandalà, Carlo Tondini
Thrombosis Research|May 4, 2010
Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and managementMario Mandalà, Roberto Labianca,
Expert Opinion on Drug Safety|August 29, 2020
Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patientsAlice Indini, Mario Mandalà
Current Opinion in Obstetrics & Gynecology|February 24, 2006
Locally advanced breast cancerSandro Barni, Mario Mandalà
Virchows Archiv : an International Journal of Pathology|December 16, 2018
Rational combination of cancer immunotherapy in melanomaMario Mandalà, Piotr Rutkowski
Critical Reviews in Oncology/Hematology|February 19, 2013
Targeting BRAF in melanoma: biological and clinical challengesMario Mandalà, Christiane Voit
Virchows Archiv : an International Journal of Pathology|February 4, 2014
Tissue prognostic biomarkers in primary cutaneous melanomaMario Mandalà, Daniela Massi
Pageof 17